Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.46 |
| ▸ | CDC25B | P30305 | 9/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12202034 | 0.94 | PTPN1 (0.46) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202025 | 0.92 | PTPN1 (0.45) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202028 | 0.92 | PTPN1 (0.45) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202036 | 0.91 | SELP (0.45) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202042 | 0.89 | PTPN1 (0.45) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202041 | 0.89 | PTPN1 (0.45) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202035 | 0.87 | PTPN1 (0.47) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202032 | 0.87 | PTPN1 (0.44) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12202027 | 0.86 | PTPN1 (0.44) | PTPN1CDC25BNT5EPTPN2PTPN6 | |
| SCHEMBL12197588 | 0.86 | SELP (0.43) | PTPN1CDC25BNT5EPTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034908-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7732583-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | SGMS1, UGCG, SGMS2 | PTPN1 3627/4885CDC25B 2234/4885NT5E 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.